Based on the aggregated intelligence of 170,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, generic-drug maker Hi-Tech Pharmacal
With that in mind, let's take a closer look at Hi-Tech's business and see what CAPS investors are saying about the stock right now.
|Headquarters (Founded)||Amityville, N.Y. (1982)|
|Market Cap||$291.45 million|
|Trailing-12-Month Revenue||$164.63 million|
|Management||Chairman/CEO David Seltzer (since 1998)
CFO William Peters (since 2004)
|Return on Equity (Average, Past 3 Years)||17%|
|Cash/Debt||$45.2 million / $756,000|
Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.
Just two weeks ago, toshimelonhead compared Hi-Tech to another potent generic play: "Hi-Tech sells generic prescription drugs, which is how people are saving money on healthcare costs. [Little debt] with much better fundamentals and more room to grow than [Perrigo
Over the past five years, in fact, Hi-Tech has grown its bottom line at an annual pace of 47.9% annually. That's faster than generic-drug stocks Mylan (3.5%), Watson (28.4%), and Teva Pharmaceutical
Last month, CAPS member Usnzth added some color to those growth numbers:
It appears that management has now figured out a working business model and their earnings for the past two years look pretty. They are in the middle of a high demand industry at a time when the population wave need more prescriptions and health care is a huge issue. They have a three prong attack on the market selling prescription drugs, generic drugs, and nutritional products.
Today, [Hi-Tech] has a P/E under 10
Minus the cash, the forward P/E is only 10
30% of shares held by insiders
What do you think about Hi-Tech, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!
Pfizer is a Motley Fool Inside Value pick. Johnson & Johnson is a choice of Inside Value and Income Investor, and Motley Fool Options has recommended a diagonal call position on it. Motley Fool Alpha owns shares of Johnson & Johnson. The Fool owns shares of Johnson & Johnson and Teva. Try any of our Foolish newsletter services free for 30 days.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.